Jun Hou

PhD

Jun Hou
MD, PhD
Room NC-1019
j.hou@erasmusmc.nl 

Professional Experience

Jun Hou studied Clinical Medicine at the University of Lanzhou, China (1995 - 2002). In 2002, she started her master program of Bioinformatics at Wageningen University, the Netherlands. During this period she conducted a research project to study TFBS in promoter regions using bioinformatics at Leiden University MC, the Netherlands. Afterwards she started her PhD training at the Department of Cell Biology at the Erasmus MC, the Netherlands. In 2010, she defended her PhD thesis entitled "Gene expression profiling of early stage non-small cell lung cancer", and continued her research at the same department as a scientific researcher. In 2012, she moved to the Department of Gastroenterology and Hepatology at the Erasmus MC to study chronic viral hepatitis by employing systems biology approaches. Her projects are parts of the Virgo consortium funded by the Dutch government and by the Netherlands Genomics Initiative (NGI) (www.virgo.nl ),which consists of 26 partners, of which 10 are private companies. 

 

Her current research and long-term interest focus on:

1) identifying novel molecular markers to predict disease progression and response to antiviral therapy of individual patients chronically infected with HBV and HCV using Affymetrix arrays, RNA-seq, and systems biology approaches; 

2) using NGS to dissect transcriptomes of immune cells, including monocytes, NK cells, and T cells in blood of chronic HBV, HCV and HIV patients, and their regulatory mechanisms modulated by therapeutic treatment; 

3) establishing an interactive network between blood transcriptomes of different immune components with NGS data to understand how immune system response cooperatively to HBV, HCV infection; 

4) developing analytic pipelines for novel research methodologies, for example RNA-sequencing of core needle biopsies, fine needle aspirate biopsies, archived FFPE tissues, and integrating multiplexing protein profiles with transcriptomics, etc. 

 

Selected references

· Hou J , Groothuismink MA, Koning L, Roomer R, van IJcken W, Liu BS, Jansen HLA, de Knegt RJ, Boonstra A. Analysis of the transcriptome and immune function of monocytes during pegylated-IFNa and ribavirin therapy in chronic HCV infection revealed induction of TLR7 responsiveness.  Antiviral Res . 2014 Sep; 109:116-24.

· Hou J , van Oord G, Groothuismink MA, Claassen M,van Ijcken W, Kreefft K, Osterhaus A, Andeweg A, Jansen HLA, de Knegt RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic HCV.  J Virol. 2014 Aug 6. pii: JVI.00775-14.

· Vanwolleghem T,  Hou J , van Oord G, Andeweg A, Osterhaus A, Pas D, Janssen HLA, Boonstra A. Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells.  Hepatology . 2015 Mar 22. doi: 10.1002/hep.27805.

· Spaan M; Claassen MA,  Hou J , Janssen HL, de Knegt RJ, Boonstra A. The intrahepatic T cell compartment does not normalize years after therapy-induced hepatitis C virus eradication.  J Infect Dis . 2015 Jan 30. pii: jiv059.

· Hou J , Boonstra A. Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients.  Antivir Ther. 2014 Sep 10. doi: 10.3851/IMP2828 

· Hou J , Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol. 2012. 7:105-114 

·  Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010. 5:e10312.